Search
Cimlanod
go.drugbank.com/drugs/DB14983InvestigationalCimlanod is under investigation in clinical trial NCT02819271 (A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers)
Propylene glycol
go.drugbank.com/drugs/DB01839ApprovedInvestigationalA clear, colorless, viscous organic solvent and diluent used in pharmaceutical preparations.
Mixtures: SYSTANE ULTRA (UD) (LUBRICANT EYE DROPS), SK Lubricant Eye DropsCategories: Compounds used in a research, industrial, or household settingMilsaperidone
go.drugbank.com/drugs/DB24348ApprovedInvestigational[L56056] On February 20, 2026, milsaperidone was approved by the FDA for the treatment of Bipolar I Disorder and schizophrenia.[L56059]
Famtozinameran
go.drugbank.com/drugs/DB17088ApprovedInvestigationalIt is administered in combination with [tozinameran] for active immunization against COVID-19 caused by SARS-CoV-2, including infection caused by Omicron BA.4/BA.5.[L43907,L43912]
Acenocoumarol
go.drugbank.com/drugs/DB01418ApprovedInvestigationalCoumarin derivatives inhibit the reduction of vitamin K by vitamin K reductase. This prevents carboxylation of vitamin K-dependent clotting factors, II, VII, IX and X, and interferes with coagulation.
Categories: Vitamin K AntagonistsDiosmin
go.drugbank.com/drugs/DB08995ApprovedInvestigationalIt is used for the improvement of capillary fragility or venous insufficiency, including chronic venous insufficiency (CVI) and hemorrhoids. … [A232885] Diosmin is a bioflavonoid isolated from various plants or synthesized from [hesperidin].
Nemtabrutinib
go.drugbank.com/drugs/DB18866InvestigationalNemtabrutinib is under investigation in clinical trial NCT05624554 (A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/small Lymphocytic … Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)).
Avizakimab
go.drugbank.com/drugs/DB18842InvestigationalAvizakimab is under investigation in clinical trial NCT03371251 (Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care).
Lazertinib
go.drugbank.com/drugs/DB16216ApprovedInvestigational[A264299, A264304] Lazertinib was first approved in South Korea on January 18, 2021, for the treatment of _EGFR_ T790M mutation-positive non-small cell lung cancer (NSCLC) with EGFR mutations. … [L51189] Lazertinib is used alone or in combination with other chemotherapeutic agents.[L51184]
Butalbital
go.drugbank.com/drugs/DB00241ApprovedIllicitThere have not been clinical trials that evaluate the clinical efficacy of butalbital in migraines [A177754] thus it is not indicated for such condition. … Due to these risks, the use of butalbital-containing combination products is typically limited for use only in cases where other medications are deemed ineffective and such usage is advised to be carefully